Elevation of serum pancreatic secretory trypsin inhibitor following serious injury. 1988

T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
Second Department of Surgery, Osaka University Medical School, Japan.

Twenty-six of 31 seriously injured patients (84%) showed a marked elevation of serum pancreatic secretory trypsin inhibitor (PSTI) to more than twice the initial level within the first 2 weeks after admission. Serum PSTI rose from the second or third post-traumatic day and reached the maximum at day 5.8 on average. In uneventful cases, it returned to the level on admission within 2 weeks. The maximum serum PSTI in these patients was significantly correlated with the severity of the injury as judged at the time of admission, indicating that the elevation of serum PSTI in these patients was related to the extent of initial damage. In contrast, serum PSTI in patients with serious complications remained at high level even at 2 weeks after trauma, and it was not correlated with the initial severity of the injury.

UI MeSH Term Description Entries
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014359 Trypsin Inhibitor, Kazal Pancreatic A secreted KAZAL MOTIF-containing serine peptidase inhibitor that inhibits TRYPSIN. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ). It protects against the trypsin-mediated premature activation of ENZYME PRECURSORS in the PANCREAS. Mutations in the SPINK1 gene are associated with CHRONIC PANCREATITIS. Acidic Pancreatic Trypsin Inhibitor,Kazal Pancreatic Trypsin Inhibitor,Pancreatic Secretory Trypsin Inhibitor, Kazal,Pancreatic Trypsin Secretory Inhibitor, Kazal,Trypsin Inhibitor, Pancreatic Secretory,Inhibitor, Tumor-Associated Trypsin,Pancreatic Secretory Trypsin Inhibitor,SPINK1,Serine Peptidase Inhibitor, Kazal-Type 1,Serine Protease Inhibitor Kazal-Type 1,Trypsin Inhibitor Kazal Pancreatic,Trypsin Inhibitor, Tumor-Associated,Tumor-Associated Trypsin Inhibitor,Serine Peptidase Inhibitor, Kazal Type 1,Serine Protease Inhibitor Kazal Type 1,Trypsin Inhibitor, Tumor Associated,Tumor Associated Trypsin Inhibitor
D014361 Trypsin Inhibitors Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. Trypsin Inhibitor,Inhibitor, Trypsin,Inhibitors, Trypsin
D014947 Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity. Injuries,Physical Trauma,Trauma,Injuries and Wounds,Injuries, Wounds,Research-Related Injuries,Wounds,Wounds and Injury,Wounds, Injury,Injury,Injury and Wounds,Injury, Research-Related,Physical Traumas,Research Related Injuries,Research-Related Injury,Trauma, Physical,Traumas,Wound

Related Publications

T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
September 1984, Clinica chimica acta; international journal of clinical chemistry,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
May 1983, Research communications in chemical pathology and pharmacology,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
July 1980, Lancet (London, England),
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
April 1980, Clinica chimica acta; international journal of clinical chemistry,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
January 1976, Methods in enzymology,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
June 2010, World journal of gastrointestinal pathophysiology,
T Shibata, and M Ogawa, and N Takata, and T Niinobu, and K Uda, and T Ukai, and M Ohta, and T Mori
January 1988, Advances in experimental medicine and biology,
Copied contents to your clipboard!